Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends

Journal of the National Cancer Institute

Volumn 94, Issue 13, 2002, Pages 981-990

  Etzioni, Ruth ^a   Penson, David F ^b   Legler, Julie M ^c   Di Tommaso, Dante ^a   Boer, Rob ^d   Gann, Peter H ^e   Feuer, Eric J ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d RAND CORPORATION   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; AUTOPSY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CAUCASIAN; COHORT ANALYSIS; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES;

EID: 0037014792     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.13.981     Document Type: Article

References (45)

1. Prostate cancer trends 1973-1995
2. SEER cancer statistics review, 1973-1999
3. Permutation tests for joinpoint regression with applications to cancer rates
4. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the USA
5. PSA testing in the US population: An analysis of Medicare claims from 1991-1998
6. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization: A dynamic population approach
7. Interpreting recent trends in prostate cancer incidence and mortality
8. Behavioral Risk Factor Surveillance System Home Page
9. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer
10. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer
11. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed?
12. Changing trends in the management of prostatic disease in a single private practice: A 5-year followup
13. 1997 American Urological Association Gallup Survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997
14. A nationwide survey of practicing urologists: Current management of benign prostatic hyperplasia and clinically localized prostate cancer
15. Alpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective alpha1 A-adrenergic antagonist
16. Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians
17. Transurethral resection of the prostate among Medicare beneficiaries: 1984-1997
18. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study
19. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute
20. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam
21. Cancer surveillance series: Interpreting trends in prostate cancer-part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
22. Vital statistics of the United States, 1992
23. Potential for cancer related health services research using a linked Medicare-Tumor registry database
24. Knowledge, attitudes and screening practices among older men regarding prostate cancer
25. The role of transurethral resection of the prostate in population-based prostate cancer incidence rates
26. Rise in prostatic cancer incidence associated with increased use of trans-urethral resection
27. Disappearance of well-differentiated carcinoma of the prostate: Effect of transurethral resection of the prostate, prostate-specific antigen and prostate biopsy
28. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia
29. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease
30. Screening for prostate cancer: Estimating the magnitude of overdetection
31. Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot Study
32. Asymptomatic incidence and duration of prostate cancer
33. Clinical evidence for and implications of the multistep development of prostate cancer
34. DEVCAN: Probability of developing or dying of cancer software
35. The validity of male patients' self-reports regarding prostate cancer screening
36. Prostate cancer screening: What we know and what we need to know
37. Estimation and prediction for cancer screening models using deconvolution and smoothing
38. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening
39. Prostate cancer histologic trends in the metropolitan Detroit area. 1982 to 1986
40. Screening for prostate cancer. A decision analytic view
41. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program
42. Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies
43. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection